The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
after optimal treatment with insulin, patients continue on insulin for four weeks
Hvidovre University Hospital
Hvidovre, Denmark
insulin-dose
Time frame: 4 weeks
24-hours glucose profiles with and without treatment of Victoza
Time frame: three days
risk of hypoglycemia during physical activity with and without Victoza
Time frame: one day
gastric emptying rate during hypoglycemia with and without Victoza
Time frame: one day
weight change from baseline, change in fructosamine from baseline
Time frame: four weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.